A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers

NCT03303911 | Terminated Phase 1 Results FDA Drug

• 1 other identifier: ACH-CYT-02
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objectives of this study are:

• To evaluate the pharmacokinetic (PK) parameters during repeat dosing of 1.5 mg or 3.0 mg cytisine when administered as the commercial 25-day schedule.
• To evaluate the pharmacodynamic (PD) effects (e.g., reduction in smoking) with repeat dosing of 1.5 mg or 3.0 mg cytisine when administered as the commercial 25-day schedule.

Conditions

Smoking Cessation

Outcome Measures

Primary Outcomes (18)

• Maximum Observed Plasma Concentration (Cmax)

  after the first dose and the last dose on Day 1; after the last dose on Days 2, 3, 12, 16, 20, 24; and after the morning dose on Day 25

• Time of Occurrence of Cmax (Tmax)

  after the first dose and the last dose on Day 1; after the last dose on Days 2, 3, 12, 16, 20, 24; and after the morning dose on Day 25

• Minimum Observed Plasma Concentration (Cmin)

  after the first dose on Days 4, 13, 17, 21 and 25

• Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Sampling Time (AUC0-t)

  after the administration of the final dose of cytisine on Day 25

• Total AUC From Time Zero to Infinity (AUC0-∞)

  after the administration of the final dose of cytisine on Day 25

• Residual Area or Percentage of Extrapolated Part for the Calculation of AUC0-∞ (%AUC)

  after the administration of the final dose of cytisine on Day 25

• Apparent Terminal Elimination Rate Constant (λz)

  after the administration of the final dose of cytisine on Day 25

• Apparent Terminal Elimination Half-Life (t1/2)

  after the administration of the final dose of cytisine on Day 25

• Number of Cigarettes Smoked Daily During Treatment and at Day 26

  Day 1 through Day 26

• Change From Baseline in Number of Cigarettes Smoked Daily up to Day 26

  Baseline, Day 1 through Day 26

• Change From Baseline in Expired Air CO up to Day 26

  Baseline, Days 4, 13, 17, 21, 26

• Number of Participants Who Ceased or Continued Smoking on Day 26

  A status of "ceased smoking" is defined as not having smoked any cigarettes for the past 24 hours on Day 26 and having an expired CO level \<10 ppm on Day 26.

  Day 26

• Change From Baseline Over Time in Urine Cotinine

  Baseline, Days 4, 13, 17, 21, 26

• Change From Baseline Over Time in TCQ-SF Score: Emotionality

  The TCQ-SF is a 12-item questionnaire that assesses 4 components of tobacco craving: emotionality (3 items), expectancy (3 items), compulsivity (3 items) and purposefulness (3 items). Responses to each item are scored from 1 (strongly disagree) through 7 (strongly disagree). Component scores are defined as the sum of the scores within each component. The total score is defined as the sum of the 4 component scores. Emotionality scores may range from 3 to 21, with lower scores indicating weaker emotional signs of tobacco craving.

  Baseline (Day -1), Days 4, 13, 17, 21, 26

• Change From Baseline Over Time in TCQ-SF Score: Expectancy

  The TCQ-SF is a 12-item questionnaire that assesses 4 components of tobacco craving: emotionality (3 items), expectancy (3 items), compulsivity (3 items) and purposefulness (3 items). Responses to each item are scored from 1 (strongly disagree) through 7 (strongly disagree). Component scores are defined as the sum of the scores within each component. The total score is defined as the sum of the 4 component scores. Expectancy scores may range from 3 to 21, with lower scores indicating less positive expectations about smoking.

  Baseline (Day -1), Days 4, 13, 17, 21, 26

• Change From Baseline Over Time in TCQ-SF Score: Compulsivity

  The TCQ-SF is a 12-item questionnaire that assesses 4 components of tobacco craving: emotionality (3 items), expectancy (3 items), compulsivity (3 items) and purposefulness (3 items). Responses to each item are scored from 1 (strongly disagree) through 7 (strongly agree). Component scores are defined as the sum of the scores within each component. The total score is defined as the sum of the 4 component scores. Compulsivity scores may range from 3 to 21, with lower scores indicating compulsion to smoke was a lesser component of tobacco craving.

  Baseline (Day -1), Days 4, 13, 17, 21, 26

• Change From Baseline Over Time in TCQ-SF Score: Purposefulness

  The TCQ-SF is a 12-item questionnaire that assesses 4 components of tobacco craving: emotionality (3 items), expectancy (3 items), compulsivity (3 items) and purposefulness (3 items). Responses to each item are scored from 1 (strongly disagree) through 7 (strongly disagree). Component scores are defined as the sum of the scores within each component. The total score is defined as the sum of the 4 component scores. Purposefulness scores may range from 3 to 21, with lower scores indicating stronger ability to not smoke.

  Baseline (Day -1), Days 4, 13, 17, 21, 26

• Change From Baseline Over Time in TCQ-SF Score: Total Score

  The TCQ-SF is a 12-item questionnaire that assesses 4 components of tobacco craving: emotionality (3 items), expectancy (3 items), compulsivity (3 items) and purposefulness (3 items). Responses to each item are scored from 1 (strongly disagree) through 7 (strongly disagree). Component scores are defined as the sum of the scores within each component. The total score is defined as the sum of the 4 component scores. Total scores may range from 12 to 84, with lower scores indicating lower tobacco craving.

  Baseline (Day -1), Days 4, 13, 17, 21, 26

Secondary Outcomes (7)

• Cytisine Amount Excreted in Urine Over Time (Ae0-24h)

  Day 1 (6 times daily at 2-hour intervals); after the administration of the single dose of cytisine on Day 25

• Percent of Drug Excreted in Urine (Ae%)

  Day 1 (6 times daily at 2-hour intervals); after the administration of the single dose of cytisine on Day 25

• Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuation of Study Drug Due to TEAEs

  From first dose of study drug through Day 26 plus 6-8 days

• Number of Participants With Clinically Significant Values in Biochemistry, Hematology, and Urinalysis

  up to Day 26

• Number of Participants With Clinically Significant Values in Vital Signs and Physical Examinations

  up to Day 26

Study Arms (2)

Cytisine 1.5 mg

EXPERIMENTAL

Multiple doses of 1.5 mg cytisine administered per 25-day schedule: * Days 1-3 (6 times daily) * Days 4-12 (5 times daily) * Days 13-16 (4 times daily) * Days 17-20 (3 times daily) * Days 21-24 (2 times daily) * Day 25 (Once daily)

Drug: Cytisine

Cytisine 3.0 mg

EXPERIMENTAL

Multiple doses of 3.0 mg cytisine administered per 25-day schedule: * Days 1-3 (6 times daily) * Days 4-12 (5 times daily) * Days 13-16 (4 times daily) * Days 17-20 (3 times daily) * Days 21-24 (2 times daily) * Day 25 (Once daily)

Drug: Cytisine

Interventions

Cytisine DRUG

film-coated tablets; depending on arm assignment, 1 or 2 tablets to be taken with 240 mL water for each dose

Also known as: Tabex

Cytisine 1.5 mg; Cytisine 3.0 mg

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Regular moderate cigarette smokers (minimum 10 cigarettes per day) who want to stop smoking.
• Urine cotinine \>500 ng/mL.
• Expired air carbon monoxide (CO) \> 11 parts per million (no cigarette 1 hour before test).
• Healthy males and females 18-65+ years of age.
• If a female subject of child bearing potential, a negative pregnancy test at screening and admission and willing to use an effective method of contraception (unless of non-childbearing potential or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of cytisine.
• If a female subject of non-child bearing potential, a negative pregnancy test at screening and admission. For the purposes of this study, this is defined as the subject being amenorrheic for at least 12 consecutive months or at least 4 months post-surgical sterilisation (including bilateral fallopian tube ligation or bilateral oophorectomy with or without hysterectomy). Menopausal status will be confirmed by demonstrating at screening that levels of follicle stimulating hormone (FSH) fall within the respective pathology reference range. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH levels are not consistent with a post-menopausal condition, determination of subject eligibility will be at Investigator's discretion following consultation with the Sponsor.
• If a male subject, willing to use an effective method of contraception (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of cytisine.
• Subject with no clinically significant abnormal serum biochemistry, haematology and urine examination values within 28 days before the first dose of cytisine.
• Subject with negative urinary drugs of abuse screen, determined within 28 days before the first dose of cytisine (a positive alcohol result may be repeated at Investigator's discretion).
• Subject with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (Hep B) and hepatitis C virus antibody (Hep C) results.
• Subject with no clinically significant abnormalities in 12-lead ECG determined after minimum of 5 minutes in supine position within 28 days before the first dose of cytisine.
• Subject with no clinically significant abnormalities in vital signs (systolic blood pressure between 90-150 mmHg (age 18-65) and 90-160 mmHg (age \>65), diastolic blood pressure (DBP) between 50 and 90 mmHg, and pulse rate (PR) between 40 110 bpm, measured on the dominant arm after minimum of 5 minutes in supine position) determined within 28 days before first dose of cytisine.
• Subject must be available to complete the study (including in-clinic stays and post study follow-up) and comply with study restrictions.
• Subject must provide written informed consent to participate in the study.

You may not qualify if:

• Treatment with smoking cessation medications (bupropion, varenicline, any nicotine replacement therapy) within 8 weeks of first dose of cytisine.
• Use of other forms of nicotine (e-cigarettes, smokeless tobacco) within 8 weeks of first dose of cytisine or are planning to use these products during study.
• Known hypersensitivity/allergy reaction to varenicline, other cytisine-derivatives or any of the excipients in the Tabex formulation.
• History of severe hypersensitivity reactions to any other drugs.
• Current treatment with antihypertensive medicinal products, statins, tuberculostatics, cholinomimetics or anticholinesterase medicinal products.
• History of any medical condition (e.g. gastrointestinal, renal or hepatic) or surgical condition (e.g. cholecystectomy, gastrectomy) that may affect drug pharmacokinetics (absorption, distribution, metabolism or excretion).
• Female subjects who are breast feeding.
• Difficulty in donating blood on either arm or known history.
• History of alcoholism or drug abuse within last 2 years.
• Use of non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days (or 5 half-lives, whichever is longer) prior to the first dose of cytisine, unless in the opinion of the Principal Investigator the medication will not interfere with the study procedures or compromise subject safety.
• Participated in any investigational drug clinical trial within the previous 3 months or a marketed drug trial within the previous 30 days prior to randomisation on Day 1.
• Donation of 450 mL or more blood or had history of significant blood loss due to any reason or had plasmapheresis within 3 months before the first dose of cytisine.
• Inability to communicate well with Principal Investigator or designees (i.e., language problem, poor mental development or impaired cerebral function).
• Any other condition that the Principal Investigator considers making the subject unsuitable for this study.

Sponsors & Collaborators

• Achieve Life Sciences: lead

Study Sites (1)

Simbec Research Ltd

Cardiff, CF11 9AB, United Kingdom

Location

MeSH Terms

Conditions

Smoking Cessation

Interventions

cytisine

Condition Hierarchy (Ancestors)

Health Behavior; Behavior

Results Point of Contact

• Title: Daniel Cain, Vice President, Clinical Research
• Organization: Achieve Life Sciences

dcain@achievelifesciences.com

425.686.1546

Study Officials

• Annelize Koch, MD

  Simbec Research Ltd (Simbec)

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 28, 2017
• First Posted: October 6, 2017
• Study Start: October 6, 2017
• Primary Completion: October 5, 2018
• Study Completion: October 5, 2018
• Last Updated: October 21, 2019
• Results First Posted: October 21, 2019

Record last verified: 2019-10

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)